

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/N9C380B7869EN.html>

Date: July 2018

Pages: 106

Price: US\$ 3,500.00 (Single User License)

ID: N9C380B7869EN

Abstracts

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 39 molecules. Out of which approximately 37 molecules are developed by companies and remaining by the universities/institutes.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (ROR?) is a protein encoded by the RORC gene. ROR? is member of the nuclear receptor family of transcription factors. It exist in two isoforms ROR? and ROR?t. ROR? is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R OR?t, appears to be highly restricted to the thymus. ROR? isoform is involved in the regulation of circadian rhythms and ROR?t plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.

The report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 21, 7 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology and Metabolic Disorders which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Metastatic Transitional (Urothelial) Tract Cancer, Neuromyelitis Optica (Devic's Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Skin Inflammation, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid

Related Orphan Receptor Gamma or RORC)

The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects

The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Boston Pharmaceuticals Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Celgene Corp

Daiichi Sankyo Co Ltd

Escalier Biosciences BV

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Johnson & Johnson

Lead Pharma Holding BV

LEO Pharma A/S

Lycera Corp

Maruho Co Ltd

Novartis AG

Nuevolution AB

Orphagen Pharmaceuticals Inc

Pfizer Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Visionary Pharmaceuticals Inc

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles

A-213 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABBV-157 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0284 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-6000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-172767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD-12681 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRC-39815 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2981278 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMU-366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-71 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3534 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-0186 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-55716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTA-1701 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Nuclear Receptor ROR Gamma for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RORC for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize RORC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize ROR Gamma for Gastrointestinal and Immunology Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Autoimmune Disorders and Psoriasis - Drug
Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-
Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-
Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory
Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-2211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGFTX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMP-778 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones

Featured News & Press Releases

Jun 20, 2018: Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of ROR gamma t

Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 1701 at the

BIO International Convention

May 30, 2018: Lycera to Present on First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 ASCO Annual Meeting

May 21, 2018: Karo Pharma Receives Milestone Payment for RORgamma Project From Pfizer

May 16, 2018: Lycera Announces Publication of Preclinical Immuno-Oncology Research, Demonstrating that Treatment with RORgamma Agonists Enhances CAR T-Cell Anti-Tumor Activity and Persistence, Resulting in Long-Lasting Anti-Tumor Memory T-Cells in an In Vivo Model

Apr 26, 2018: Nuevolution obtains new data in its internal RORt program supporting effect in human inflammatory bowel diseases

Apr 17, 2018: Lycera Presents Clinical Safety and Dose Selection Results for First-in-class RORgamma Agonist Candidate LYC-55716 at the 2018 AACR Annual Meeting

Apr 05, 2018: Lycera to Present Clinical Results and Supporting Preclinical Data for First-In-Class RORgamma Agonist LYC-55716 at the 2018 AACR Annual Meeting

Apr 03, 2018: Reata to Present Preclinical Data on RTA 1701, a Novel RORt Inverse Agonist, at Upcoming Immunology Conference

Mar 16, 2018: Reata to Present on its Autoimmune and Inflammatory Disorders Drug Candidate at the BIO Asia International Conference

Jan 04, 2018: Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab

Nov 21, 2017: Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments

Nov 07, 2017: Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer's (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716

Oct 19, 2017: Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a

Oct 04, 2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by Boston Pharmaceuticals Inc, H2 2018
Pipeline by Brickell Biotech Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Escalier Biosciences BV, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Genfit SA, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Lead Pharma Holding BV, H2 2018
Pipeline by LEO Pharma A/S, H2 2018
Pipeline by Lycera Corp, H2 2018

Pipeline by Maruho Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Nuevolution AB, H2 2018
Pipeline by Orphagen Pharmaceuticals Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Phenex Pharmaceuticals AG, H2 2018
Pipeline by Reata Pharmaceuticals Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pipeline by Visionary Pharmaceuticals Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

COMPANIES MENTIONED

AbbVie Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Boston Pharmaceuticals Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

Celgene Corp

Daiichi Sankyo Co Ltd

Escalier Biosciences BV

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Johnson & Johnson

Lead Pharma Holding BV

LEO Pharma A/S

Lycera Corp

Maruho Co Ltd

Novartis AG

Nuevolution AB

Orphagen Pharmaceuticals Inc

Pfizer Inc

Phenex Pharmaceuticals AG
Reata Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Visionary Pharmaceuticals Inc

I would like to order

Product name: Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/N9C380B7869EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N9C380B7869EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970